Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS

292008

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS

Interim data from a Phase 2 trial of Immunic Therapeutics’ investigational oral therapy IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis (RRMS) patients has established a once-daily, 30 mg dose as the most appropriate for future Phase 3 trials. The company is now in discussions with regulatory authorities, including those in the U.S. and Europe, regarding pivotal Phase 3 testing expected to start later this year.  At the request of the U.S. Food and Drug Administration (FDA),…

You must be logged in to read/download the full post.